Use of phosphodiesterase 5 inhibitors is not associated with ocular adverse events.

ABSTRACT:

Background

Phosphodiesterase 5 inhibitor (PDE5i) use has been linked to a number of ocular side effects, such as serous retinal detachment (SRD), retinal vascular occlusion (RVO), and ischemic optic neuropathy (ION).

Aim

We investigated the risk for SRD, RVO, and ION in patients using PDE5is.

Methods

We utilized the IBM MarketScan (2007-2021) Commercial and Medicare Supplemental Databases (version 2.0) for this analysis. To estimate overall events risk, Cox proportional hazard models were applied to calculate the hazard ratios (HRs) for erectile dysfunction (ED) diagnosis and the different treatments, adjusting for region, median age, obesity, diabetes mellitus, hyperlipidemia, smoking, hypertension, coronary artery disease, and sleep apnea. Additionally, the same ana

SUBMITTER: Belladelli F 

PROVIDER: S-EPMC11537286 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature